SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant volatility and trending status driven by intense speculation around a potential short squeeze, with community members highlighting an increasing cost-to-borrow rate and low share availability. Investors are closely monitoring the upcoming earnings report, viewing it as a critical catalyst while debating the company's valuation and the effectiveness of its growth strategy compared to broader AI sector trends.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing intense volatility as the community speculates on technical breakouts and potential short-squeeze activity fueled by social media buzz. Investors remain divided, with some betting on a rapid move upward based on technical patterns, while others express frustration over the stock's persistent sideways movement and lack of major corporate news.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending following the announcement of a massive $2.8 billion AI infrastructure expansion with Yotta Data Services, which has reignited intense community debate regarding the company's valuation, contract execution risk, and short-interest dynamics. While bullish investors point to the significant project pipeline and strategic partnerships as signs of a pending breakout, bears continue to express skepticism regarding the company's revenue recognition, lack of formal guidance, and history of unfulfilled promises.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is currently trending as investors weigh the company's recent earnings beat and strategic capital moves against ongoing concerns regarding high cash burn and dilution risk. Community discussion is heavily focused on the company's long-term potential tied to the R2 platform ramp-up and production milestones, with investors debating whether current price levels present a buying opportunity or a signal of deeper volatility.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors digest news of potential FDA leadership changes, with the community closely tracking rumors of a former company VP being considered for a key regulatory role. The optimism is fueled by strong HOPE-3 Phase 3 clinical data for its lead therapy, leading many to believe that the path to approval is nearing completion despite recent price volatility caused by speculative short-selling.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending as traders speculate on potential price appreciation, driven by a recent licensing agreement and anticipation of clinical data presentations. While some community members are focused on a possible short squeeze and technical breakouts, others remain cautious, citing risks associated with the company's capital structure and previous stock performance.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox shares are under significant downward pressure following a guidance cut that cited user growth friction caused by new age-verification and safety measures. While some community members view the dip as an oversold buying opportunity, others are heavily focused on the company's lack of profitability and the broader debate surrounding platform safety.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing heavy retail interest and positive price momentum as investors speculate on the potential for its proprietary electro-optic polymer technology to become a critical component in next-generation AI and high-speed data center infrastructure. The community is actively debating the company's path toward commercialization and watching for potential institutional partnerships or licensing deals that could validate its long-term growth potential.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing intense momentum as the community monitors its aggressive expansion plans, including a significant footprint increase in Houston to meet massive demand for 800G and 1.6T transceivers. While bullish investors view this scaling as proof of institutional demand and a clear supply chain advantage, bears are highlighting concerns regarding the company's valuation, history of losses, and potential insider selling.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS Tech Inc. is generating intense community interest driven by micro-float momentum and speculative trading dynamics often seen in low-float, high-volatility setups. Traders are actively debating the sustainability of the stock's recent price action, with some highlighting potential for short squeezes while others warn of risks related to debt and dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The study evaluated the device’s ability to detect codeine in 40 adults.</li><li>The company has begun the second phase of its program, which is expected to be completed by June 2026.</li><li>Intelligent Bio Solutions will also begin an Interference Study to evaluate how the device performs in real-world environments.</li></ul>Intelligent Bio Solutions (INBS) announced on Thursday the successful completion of its initial clinical study, which is needed to seek U.S. Food and Drug Administration (FDA) approval for its fingerprint-based drug testing system.Despite the seemingly positive update, <a href="https://stocktwits.com/symbol/INBS">INBS shares</a> slumped 10% on Thursday, following a 7% decline in the previous session.<h2 class="st-heading-2">What Was The Study About?</h2>The study evaluated the device’s ability to detect codeine in 40 adults and confirmed its accuracy using standard laboratory testing methods. INBS added that it has begun the second phase of its program, which it expects to complete by June 2026.Alongside the Method Comparison and Usability Study, the company will also begin an Interference Study to evaluate how the device performs when exposed to substances commonly found in real-world environments. The study is expected to be completed by the end of July 2026."The U.S. drug screening market is a significant commercial opportunity for Intelligent Bio Solutions. The on-schedule completion of our Cut-off Study validates our clinical approach and keeps us firmly on track toward our FDA 510(k) submission and planned commercial launch," said Harry Simeonidis, President and CEO at INBS.The company said its non-invasive fingerprint technology has advantages over traditional urine, oral fluid, and blood testing methods.&nbsp;Last week, the company received European Patent EP3752831, which relates to improving fingerprint chemical analysis by accounting for fingerprint deposition volume. This marks the company’s eighth European patent.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits remained 'bullish' over the past 24 hours, amid 'high' message volumes.One user said the stock will climb back up to $3 by Monday.<stembedurl>https://stocktwits.com/tommycman/message/649278493</stembedurl>Year-to-date, the stock has slumped more than 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

ZoomInfo said net revenue retention was stable for the third consecutive quarter. 

INBS Stock Falls After Clinical Study Win: FDA Progress Fails To Lift Shares 

The company completed its initial clinical study required for FDA approval of its fingerprint-based drug-testing system.

Equity

<ul class="summary-bullets"><li>The devices are being deployed across construction, transportation, logistics, and manufacturing sectors in the U.K. and Europe.</li><li>The company expects additional shipments in 2026 as it prepares for U.S. market entry.</li><li>Intelligent Bio Solutions expects to reduce annual production costs by more than 40%, which could lift gross margins by around 20 percentage points each year.</li></ul>Shares of Intelligent Bio Solutions Inc. (INBS) reversed their pre-market gains to trade 2% lower on Wednesday, after the company announced the rollout of the first shipment of its Intelligent Fingerprinting Drug Screening Readers produced under a new manufacturing partnership with Syrma Johari MedTech.The devices are being deployed across construction, transportation, logistics, and manufacturing sectors in the U.K. and Europe. Intelligent Bio Solutions also doubled its in-house production capacity for test strips. The company expects additional shipments in 2026 as it prepares for U.S. market entry.<h2 class="st-heading-2">Expanded Capacity To Boost Margins</h2>The company has added advanced manufacturing equipment, increasing its cartridge output, enabling Intelligent Bio Solutions to develop expanded drug-testing panels for different customer and regulatory needs.The medical technology company said its manufacturing capacity is now about four times higher than before. As a result, it expects to reduce annual production costs by more than 40%, which could lift gross margins by around 20 percentage points each year.“We are building a vertically integrated, cost-efficient manufacturing engine that supports margin expansion, accelerates innovation, and positions us to enter the U.S. market with operational strength and the capacity to grow with demand,” said Callistus Sequeira,&nbsp;VP of Global Quality &amp; Operations at Intelligent Bio Solutions.&nbsp;Earlier this month, INBS reported a 48% increase in second-quarter (Q2) revenue to $896,774, driven by a 104% surge in reader sales.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.&nbsp;Year-to-date, <a href="https://stocktwits.com/symbol/INBS">INBS stock</a> is down 47%For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

INBS Stock Reverses Early Gains After First Shipment of Drug Screening Readers Under Syrma Johari MedTech Partnership

The company announced the first shipment of its Intelligent Fingerprinting Drug Screening Readers, produced in collaboration with Syrma Johari MedTech.

<ul class="summary-bullets"><li>On Dec. 31, 2025, INBS stock closed over 132% after announcing a manufacturing partnership with Syrma Johari MedTech.</li><li>The company also announced a private placement with two healthcare-focused institutional investors to issue 2.3 million shares of common stock.</li><li>Intelligent Bio Solutions had announced a 1-for-10 reverse stock split effective Dec. 15.</li></ul>Shares of Intelligent Bio Solutions (INBS) have seen strong buying interest in recent weeks, with the stock adding more than 35% in premarket trading on Monday.&nbsp;From the close on Dec. 30, 2025, to Jan. 9, 2026, <a href="https://stocktwits.com/symbol/INBS">INBS stock</a> has surged about 337%, breaching both its 50-day moving average (50-DMA) and the longer-term 200-DMA during the rally.This stellar rally has made it a momentum favorite among retail traders, driven by a recent manufacturing partnership, fresh capital boost, and a compliance update with Nasdaq; however, concerns around dilution and its volatile ride continue to temper sentiment.&nbsp;<h2 class="st-heading-2">What Led To INBS Rally?</h2>On Dec. 31, 2025, INBS stock closed over 132% after announcing a manufacturing partnership with Syrma Johari MedTech to scale production of its fingerprint drug-screening reader. The deal is expected to cut annual production costs by over 40% and lift gross margins by about 20 percentage points, while expanding manufacturing capacity fourfold, Intelligent Bio Solutions said. The company said the deal positions it well for its U.S. market launch in 2026.The company also announced a private placement with two healthcare-focused institutional investors to issue 2.3 million shares of common stock along with Series K-1 and K-2 warrants for the same number of shares at $4.35 each, raising around $10 million before fees. The warrants have an exercise price of $4.10 per share.Separately, on January 7, Intelligent Bio Solutions was notified by Nasdaq that it had regained compliance to trade on the Nasdaq Capital Market. The closing bid price of INBS stock had remained at $1.00 or higher for 14 consecutive business days, from Dec. 16, 2025, to Jan. 6, 2026. The company had announced a 1-for-10 reverse stock split effective Dec. 15.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the bullish premarket movement, retail sentiment on Stocktwits remained in the ‘neutral’ zone over the past 24 hours. INBS was among the top-trending tickers on Stocktwits at the time of writing.One user thinks short interest is extremely high and predicts the stock could fall to $15. It is currently trading at $24.2.<stembedurl>https://stocktwits.com/Harsh1210/message/641505295</stembedurl>However, another user sees a setup that pits the company’s operational progress against short-term dilution fears.<stembedurl>https://stocktwits.com/Atdanaiw/message/641502687</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/silver-gold-record-highs-analyst-michael-oliver-predicts-500-breakout/cmU9UNvR4Ec">Silver’s Next Move Could Be Explosive: Michael Oliver Sees $200–$500 Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

INBS Stock Has Surged Over 330% So Far In January – But Retail Traders Are Warning Of A Pullback 

INBS shares were up more than 35% in premarket trading on Monday and were among the top trending tickers on Stocktwits.

INBS Stock Gains Triple-Digit Rally So Far In January: What’s Driving The Surge And What Traders Are Saying

Why Intelligent Bio Solutions Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session

INBS Stock Surges 132.4% on New Manufacturing Partnership 

Intelligent Bio Solutions' stock jumps after a new manufacturing partnership aimed at cutting costs, boosting margins and scaling production ahead of U.S. expansion.

Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026 Baidu, Rubico, Intelligent Bio Solutions In Focus

U.S. stock futures rose on the first trading day of the year on Friday after missing the Santa Claus rally over the truncated week. Futures of major benchmark indices were higher. The Santa Claus...

<ul class="summary-bullets"><li>Retail sentiment improved for SPY and QQQ on Stocktwits.</li><li>Traders are eyeing Tesla’s delivery data and a surge in silver prices.</li><li>Baidu drew retail attention after its chip unit filed for an IPO.</li></ul>U.S. stock futures were trading higher early Friday as markets reopened for the first full trading session of 2026. Wall Street is looking to break a three-year streak of opening-day losses. The S&amp;P 500 has had a negative close on its first trading day&nbsp;in each of the last three years (2023-2025).As of 2:50 a.m. ET on Friday, Nasdaq 100 futures were up 0.7%, S&amp;P 500 futures rose 0.4%, and the Dow futures gained 0.1%, while Russell 2000 futures rose 0.4%.On Stocktwits, the retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, moved to ‘bullish’ from ‘neutral’ a day ago. And sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bullish’, amid low message volumes.&nbsp;<h2 class="st-heading-2">Trending Stocks To Watch</h2> Baidu (BIDU): Trending following news that its chip unit filed for an IPO, sparking a renewed interest in ‘China AI’ discount plays. Tesla (TSLA): High search volume and social chatter ahead of its Q4 delivery report expected today. Meanwhile, reports suggest that China’s BYD has officially dethroned it as the global EV king for the full year 2025. NIO is trending high on Stocktwits as well.&nbsp; Watch out for&nbsp;iShares Silver Trust (SLV):&nbsp;Silver jumped 2.5% in early trading, building on its best annual performance since 1979.Stellantis (STLA): The company is resurrecting a gas-powered Ram pickup truck, the TRX, with a V-8 engine, as it faces fewer federal emissions regulations, CNBC reported.Other noteworthy tickers trending on Stocktwits at the time of writing were Intelligent Bio Solutions (INBS), BigBear.ai (BBAI), Corcept Therapeutics (CORT), and Sensei BioTherapeutics (SNSE).&nbsp;<h2 class="st-heading-2">Other Catalysts To Watch</h2>On the economic front, investors are looking ahead to the release of the Fed Balance Sheet (4:30 PM ET). Markets will be eyeing updates on ‘Quantitative Tightening’ (QT) pacing. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Point To Strong New-Year Open On Wall Street: Why TSLA, BIDU, SLV, STLA Are On Traders' Radar Today

Wall Street is hoping to break a three-year streak of opening-day losses.

Top Medical Stocks To Consider - January 1st

Eli Lilly and Company, UnitedHealth Group, Intelligent Bio Solutions, Johnson & Johnson, Merck & Co., Inc., Pfizer, and Corcept Therapeutics are the seven Medical stocks to watch today, according to...

Intelligent Bio Solutions Stock Surges 188% On New Manufacturing Partnership

(RTTNews) - Intelligent Bio Solutions Inc. (INBS) shares jumped 187.68%, trading at $11.80, up $7.70, after the company announced a new manufacturing partnership aimed at strengthening global...

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

INBS
Intelligent Bio Solutions Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INBS News

INBSIntelligent Bio Solutions Inc